<DOC>
	<DOC>NCT02397473</DOC>
	<brief_summary>The main purpose of this study is to evaluate the efficacy and safety of the study drug known as LY2951742 in participants with episodic cluster headaches.</brief_summary>
	<brief_title>A Study of LY2951742 in Participants With Episodic Cluster Headache</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Cluster Headache</mesh_term>
	<criteria>Participants with a history of episodic cluster headache with at least two cluster periods lasting from 7 days to 1 year (when untreated) and separated by painfree remission periods of â‰¥1 month. Participants are able to distinguish cluster headache attacks from other headaches. Current enrollment in or discontinuation within the last 30 days from, a clinical trial involving any investigational drug or device. Current use or any prior exposure to any calcitoningenerelated peptide (CGRP) antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF). Are taking indomethacin and/or are suspected of having another distinct trigeminal autonomic cephalalgia. A history of migraine variants that could implicate or could be confused with ischemia. Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic proteins. A history or presence of other medical illness that indicates a medical problem that would preclude study participation. Evidence of significant active or unstable psychiatric disease, in the opinion of the investigator. Women who are pregnant or nursing.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>